Cargando…

Naturally Occurring Resistance Associated Substitutions in Non-Cirrhotic, Treatment Naive HCV–HIV Co-Infected Patients Does Not Affect the Treatment Response for Anti-HCV Antiviral Therapy

PURPOSE: Limited literature on the prevalence of baseline resistance associated substitutions (BL-RAS) among HCV–HIV co-infected patients and their association with treatment outcomes is available especially from India. Hence, the present study aimed to study naturally occurring RAS among non-cirrho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Ekta, Agarwal, Reshu, Rastogi, Aayushi, Rani, Nitiksha, Jindal, Ankur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052117/ https://www.ncbi.nlm.nih.gov/pubmed/33880042 http://dx.doi.org/10.2147/IDR.S301032

Ejemplares similares

Antiviral therapy of HCV in the cirrhotic and transplant candidate
por: Herrine, Steven K., et al.
Publicado: (2006)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2012)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
por: Reau, Nancy, et al.
Publicado: (2023)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Occult HCV Infection (OCI) Diagnosis in Cirrhotic and Non-cirrhotic Naïve Patients by Intra-PBMC Nested Viral RNA PCR
por: Abd Alla, Mohamed Darwish Ahmed, et al.
Publicado: (2017)

Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
por: Raj, V. Stalin, et al.
Publicado: (2017)

Baseline Plasma Metabotype Correlates With Direct-Acting Antiviral Therapy Nonresponse for HCV in HIV–HCV Coinfected Patients
por: Tripathi, Gaurav, et al.
Publicado: (2022)

Enterococcus gallinarum Spontaneous Bacterial Peritonitis in an HCV Cirrhotic
por: Abidali, Hussein, et al.
Publicado: (2015)

Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
por: Li, Zhanyi, et al.
Publicado: (2017)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Naturally Occurring Mutations in the Nonstructural Region 5B of Hepatitis C Virus (HCV) from Treatment-Naïve Korean Patients Chronically Infected with HCV Genotype 1b
por: Kim, Dong-Won, et al.
Publicado: (2014)

Treatment Response and Drug Resistance Profiling of Genotype 6 of Hepatitis C Virus in HCV/HIV Co-Infected Patients: A Pilot Study from INDIA
por: Gupta, Ekta, et al.
Publicado: (2022)

Lower Rates Of Naturally Occurring Resistance-Associated Substitutions (RASs) In Hepatitis C Virus (HCV)-Infected Chronic Kidney Disease (CKD) Patients Than In HCV-Infected Patients With Only Liver Disease
por: Gupta, Ekta, et al.
Publicado: (2019)

Antiviral resistance in HCV strains isolated from Romanian patients with limited treatment options for chronic HCV infection
por: Streinu-Cercel, Anca, et al.
Publicado: (2014)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Resistant-Associated Substitutions Do Not Affect HCV RNA and HCV Core Antigen Clearance During Direct-Acting Antiviral Agent Treatment in a Real-World Setting
por: Chen, Hongyu, et al.
Publicado: (2022)

Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions
por: Bagaglio, Sabrina, et al.
Publicado: (2019)

Transcriptomic Assay of CD8(+) T Cells in Treatment-Naïve HIV, HCV-Mono-Infected and HIV/HCV-Co-Infected Chinese
por: Zhao, Jin, et al.
Publicado: (2012)

Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China
por: Zhou, Kali, et al.
Publicado: (2016)

Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China
por: Li, Zhanyi, et al.
Publicado: (2017)

Evaluation of impact of occult hepatitis B infection in chronic HCV-infected patients: A retrospective cohort study
por: Bhatia, Mohit, et al.
Publicado: (2018)

356. HIV-HCV Coinfection: An Investigation of CD4 T-Cell Reconstitution after HCV Direct-Acting Antiviral Treatment
por: Michienzi, Sarah M, et al.
Publicado: (2019)

Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients
por: Marascio, Nadia, et al.
Publicado: (2016)

Performance evaluation of NeuMoDx 96 system for hepatitis B and C viral load
por: Chooramani, Gagan, et al.
Publicado: (2023)

Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients
por: Chen, Zhi-wei, et al.
Publicado: (2017)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Immunological Dynamics Associated with Direct-Acting Antiviral Therapies in Naive and Experimented HCV Chronic-Infected Patients
por: Pereira, Grenda Leite, et al.
Publicado: (2019)

An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA
por: Hansoongnern, Payuda, et al.
Publicado: (2023)

Silent damage? Occult HCV replication and histological disease may occur following apparent HCV clearance
por: Manickam, Cordelia, et al.
Publicado: (2019)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Transplantation of HCV Viremic Livers into HCV Viremic Recipients Followed by Direct-acting Antiviral Therapy
por: Kapila, Nikhil, et al.
Publicado: (2019)

Assessment of HCV-RNA test results and access rates to antiviral treatment in patients with anti-HCV positivity—a 10-year analysis
por: TÜRKOĞLU YILMAZ, Emine, et al.
Publicado: (2022)

Towards HCV extinction with modern HCV treatment? “Yes we can!”
por: Torti, C, et al.
Publicado: (2012)

Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013)

Substituted imidazopyridines as potent inhibitors of HCV replication()
por: Vliegen, Inge, et al.
Publicado: (2009)

Personality dysfunction in opiate addicts on opioid substitution treatment and the risk of HCV infection
por: Skočibušić, Siniša, et al.
Publicado: (2022)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
por: Forns, Xavier, et al.
Publicado: (2015)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tm4ldnebnkvfip9jemeqv42ggr